TJ-L1I7

N/A

Report date: 2025/05/14 14:17:06

Base Information

Drug NameTJ-L1I7

Drug Alias NameTJ-L1I7

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionProgrammed death-ligand 1 blockersInterleukin-7 receptor subunit alpha modulators

TargetsProgrammed death-ligand 1Interleukin-7 receptor subunit alpha

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesI-Mab Biopharma Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesI-Mab Biopharma Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A